logo
  

Hovnanian Enterprises Posts Loss In Q3; Total Revenues Down 1.9% - Quick Facts

Hovnanian Enterprises, Inc. (HOV), a leading national homebuilder, reported a third-quarter net loss of $7.7 million, or $0.05 per common share, compared to net income $17.1 million, or $0.11 per share, prior year. The pre-tax loss, excluding land-related charges and loss on extinguishment of debt, was $8.9 million compared to net income of $16.1 million in the prior year's third quarter.

On average, five analysts polled by Thomson Reuters expected the company to report a loss per share of $0.01 for the quarter. Analysts' estimates typically exclude special items.

Total revenues were $540.6 million, a decrease of 1.9% compared to $551.0 million, prior year. Analysts expected revenue of $611.95 million for the quarter. Consolidated deliveries were 1,408 homes, a 3.8% decrease compared with 1,464 homes, prior year.

In the third quarter of fiscal 2015, the number of consolidated net contracts increased 13.0% to 1,533 homes compared with 1,357 homes in the prior year's third quarter. The dollar value of consolidated net contracts increased 19.7% to $619.4 million for the three months ended July 31, 2015 compared with $517.3 million during the same quarter a year ago.

Hovnanian expects total revenues for the fourth quarter to be approximately $745 million and pretax profit excluding land related charges, gains or losses on extinguishment of debt and other non-recurring items such as legal settlements are expected to be approximately $22 million. Analysts expect the company to report revenue of $724.70 million.

The company expects total revenues for fiscal 2016 to be between $2.7 billion and $3.1 billion and pretax profit excluding land related charges, gains or losses on extinguishment of debt and other non-recurring items such as legal settlements expected to be between $40 million and $100 million for all of fiscal 2016. Analysts expect the company to report revenue of $2.25 billion.

Ara Hovnanian, CEO, said: "During the third quarter the dollar value of our contract backlog increased 23% year-over-year, while the dollar value of our net contracts increased 20% compared to last year's third quarter, and we also had a 170 basis point sequential improvement in our quarterly gross margin. Assuming no changes in market conditions, we are on track for solid profitability during the fourth quarter of fiscal 2015 and are well positioned for a breakout year from the perspective of deliveries and revenues which should lead to profitability in fiscal 2016."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT